Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766621 · ClinicalTrials.gov registry record · Phase 1
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02766621 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 62 participants.
The verdict
NCT02766621, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of PF 06823859 in healthy subjects.
Interventions
- BIOLOGICAL PF-06823859
- DRUG Placebo injection SC/IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2017-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02766621
The ClinicalTrials.gov registry entry for NCT02766621 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06823859 is the first listed.
NCT02766621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02766621 about?
NCT02766621 is a clinical study titled "Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859". The purpose of this study is to determine the safety, tolerability and pharmacokinetics of escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of PF 06823859 in healthy subjects.
What is the current status of trial NCT02766621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-05-27. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT02766621?
The interventions under investigation include: PF-06823859 (BIOLOGICAL), Placebo injection SC/IV (DRUG).
Who is sponsoring clinical trial NCT02766621?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.